Inhalerx Ltd (IRX) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.044x

Based on the latest financial reports, Inhalerx Ltd (IRX) has a cash flow conversion efficiency ratio of -0.044x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$38.91K ≈ $27.53K USD) by net assets (AU$-877.11K ≈ $-620.61K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Inhalerx Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Inhalerx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Inhalerx Ltd total liabilities for a breakdown of total debt and financial obligations.

Inhalerx Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Inhalerx Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Beowulf Mining PLC
ST:BEO-SDB
N/A
Anagenics Ltd
AU:AN1
-0.286x
Henderson International Income Trust PLC
LSE:HINT
0.024x
EPRCOMUNICAZIONE S.P.A.
F:J3P
N/A
ASIA Capital Group Public Company Limited
BK:ACAP
0.032x
Fastpasscorp A/S
CO:FASTPC
0.246x
Cosmo Metals Ltd
AU:CMO
-0.035x
Sulliden Minerals SA
TO:SMC
0.090x

Annual Cash Flow Conversion Efficiency for Inhalerx Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of Inhalerx Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Inhalerx Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 AU$-63.97K
≈ $-45.26K
AU$-368.77K
≈ $-260.93K
5.765x +295.55%
2023-12-31 AU$665.47K
≈ $470.86K
AU$-1.96 Million
≈ $-1.39 Million
-2.948x -203.82%
2022-12-31 AU$1.90 Million
≈ $1.35 Million
AU$-1.85 Million
≈ $-1.31 Million
-0.970x -126.23%
2021-12-31 AU$2.68 Million
≈ $1.89 Million
AU$-1.15 Million
≈ $-812.69K
-0.429x +47.70%
2020-12-31 AU$1.32 Million
≈ $936.76K
AU$-1.09 Million
≈ $-768.25K
-0.820x +85.05%
2019-12-31 AU$340.08K
≈ $240.63K
AU$-1.87 Million
≈ $-1.32 Million
-5.487x -613.06%
2018-12-31 AU$2.68 Million
≈ $1.90 Million
AU$-2.06 Million
≈ $-1.46 Million
-0.770x -35.45%
2017-12-31 AU$4.51 Million
≈ $3.19 Million
AU$-2.56 Million
≈ $-1.81 Million
-0.568x -1717.88%
2016-12-31 AU$7.33 Million
≈ $5.19 Million
AU$-229.03K
≈ $-162.05K
-0.031x --

About Inhalerx Ltd

AU:IRX Australia Biotechnology
Market Cap
$4.18 Million
AU$5.91 Million AUD
Market Cap Rank
#28669 Global
#1620 in Australia
Share Price
AU$0.02
Change (1 day)
+4.35%
52-Week Range
AU$0.02 - AU$0.05
All Time High
AU$0.39
About

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexali… Read more